U.S. stock night trading volatility: FDA accepts RP1 application causing stock price roller coaster, Replimune down 3.07% in night trading

U.S. Stock Night Market Movements Replimune fell 3.07% in the night market. According to recent important news: On October 20, the U.S. FDA accepted Replimune's supplemental application for its RP1 drug, which is used for the treatment of advanced melanoma. This news drove the company's stock price up over 100% in pre-market trading, but it subsequently experienced a pullback. On October 20, Leerink Partners raised Replimune's target price from $3 to $13, reflecting the market's optimistic expectations for its future growth potential. On October 20, Replimune's stock price surged to a trading volume of 51 million shares following the release of significant news, far exceeding the three-month average daily trading volume of 4.13 million shares, indicating high market attention on the stock. The biotechnology industry is highly volatile, and market risks should be monitored. Stocks with High Trading Volume in the Industry Recursion rose 0.30% in the night market. According to recent important news: On October 21, Recursion Pharmaceuticals CEO Christopher Gibson sold 100,000 shares and converted 120,000 shares of Class B common stock into Class A common stock. This action may raise market concerns about internal confidence in the company, leading to stock price fluctuations. On October 19, Straits Research projected that the AI-driven drug discovery market will grow at an annual rate of 32% by 2030. This optimistic market outlook may drive Recursion's stock price up. No other significant news recently. The AI drug market has great growth potential, but volatility risks should be monitored. Moderna rose 0.62% in the night market. According to recent important news: On October 20, Moderna's mRNA COVID-19 vaccine was found to enhance the effectiveness of cancer immunotherapy. The research results were presented at the European Society for Medical Oncology conference in Berlin, showing an extended survival period for cancer patients after vaccination. This news drove Moderna's stock price up over 5%. Data source: Stat News On October 20, Moderna released documents regarding the safety and immunogenicity of its mRNA-1018 candidate vaccine, which is used to prevent H5N1 influenza, attracting market attention due to the related research results. Data source: Public Technologies On October 20, Moderna's mRNA-4359 cancer antigen therapy demonstrated positive response rates at the ESMO conference, particularly in patients with high PD-L1 expression. Although the results are encouraging, the data still requires further validation. Data source: Joseph Stringer analysis report. The volatility in the biotechnology sector is increasing, and risks should be monitored CRISPR therapy rose 0.45% in after-hours trading. There have been no significant news recently; trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. The innovation trend in the healthcare industry is notable, and risks should be monitored